Dr. Myriam Mendila
Chief Scientific Officer Head R&D
Dr. Myriam Mendila joined CureVac from Novartis, Switzerland, where she served as Chief Medical Officer in the Oncology Business Unit and was responsible for the worldwide medical affairs function. In this role, Dr. Mendila was a member of several governance boards, including the Oncology Leadership Team, the Scientific Development Leadership Team, and the Development Committee Novartis. Prior to that, she held leadership positions of increasing responsibility within Global Medical Affairs, US Medical Affairs, Global Product Development, and Global Product Strategy at Roche/Genentech.
Dr. Mendila holds an MD from the Medical School Hanover. She has published research papers in journals including AIDS, The Lancet, the Journal of Clinical Oncology, Annals of Oncology, and The Lancet Oncology